Algernon Pharmaceuticals Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Algernon Pharmaceuticals Inc, recently renamed Algernon Health Inc, is a Canadian healthcare company focused on brain-specific diagnostics and pharmaceutical development. The company operates primarily in North America and specializes in establishing specialized neuroimaging clinics for early-stage detection and treatment of Alzheimer's Disease (AD) using FDA-cleared and Medicare/Medicaid-covered brain-specific Positron Emission Tomography (PET) scanning systems that detect amyloid plaques with reduced radiation exposure compared to conventional PET/CT machines. Algernon's core products and services include the provision of dedicated neuroimaging clinics offering PET brain scans for AD, dementia, epilepsy, neuro-oncology, and movement disorders; Alzheimer's medication infusion services for FDA-approved therapies such as Kisunla and Leqembi; cognitive function assessments; genetic screening; blood testing; and wellness counseling. The company also continues pharmaceutical development through its private subsidiary Algernon NeuroScience, which conducts research on a proprietary form of DMT for stroke and traumatic brain injury recovery. Additionally, Algernon holds a 20% equity stake in Seyltx, a U.S.-based drug development firm advancing Ifenprodil for chronic cough treatment after acquiring the research program from Algernon. Recent major developments include Algernon’s formal rebranding from Algernon Pharmaceuticals to Algernon Health to reflect its strategic shift toward the Alzheimer’s diagnostic market and neuroimaging clinic rollout across North America; the acquisition of NoBrainer Imaging Centers, Inc. to facilitate the establishment of Alzheimer's diagnostic and treatment medical clinics; signing a multi-million-dollar equipment and financing agreement with Catalyst MedTech for Oncovision CareMiBrain PET scanner systems; closing multiple private placement financings in 2025 to support expansion; and advancing clinical programs via Algernon NeuroScience, including appointing Validcare as CRO for its Phase 2a DMT human stroke trial. These strategic moves aim to leverage neuroimaging technologies and proprietary pharmaceuticals to capture an emerging healthcare market for neurodegenerative and brain injury conditions while maintaining active drug repurposing and new therapeutic pipelines. The company was founded with headquarters in Vancouver, British Columbia.
Grey Matters Takes Delivery of the First Brain Dedicated PET Scanning System for its Flagship NovaScan Neuroimaging Clinic in Florida
Grey Matters Announces Increase to Private Placement Financing to $1.25 Million and Closing of Offering
Grey Matters Closes First Tranche of $500,000 of its Private Placement Financing
Grey Matters Improves Warrant Terms of Private Placement
Grey Matters Improves Warrant Terms of Private Placement
Grey Matters Health Signs LOI with Catalyst MedTech for 200 Brain PET Scans for Alzheimer's Clinical Trial at 2nd NovaScan Location Planned for Tampa
Grey Matters Announces Private Placement
Algernon Health Announces Effective Date of Previously Announced Name Change to “Grey Matters Health Inc.” and its 10:1 Share Consolidation
Algernon Health announces effective date of name change to Grey Health Matters
Algernon Health to rebrand as Grey Matters Health, sharpen focus on Alzheimer's diagnostics
Algernon Health Announces Proposed Name Change to “Grey Matters Health Inc.” and a 10:1 Share Consolidation
Algernon Health CEO outlines US brain imaging network plans - ICYMI
Algernon Health CEO outlines US brain imaging network plans - ICYMI
Small Cap Watch: Lindian, Critical Resources, Resokution Minerals and more...
Algernon Health highlights NovaScan brand for dedicated brain PET scanning centers
Estee Lauder’s potential merger with Puig seen as transformational move
Algernon Health Announces NOVASCAN NEUROIMAGING CLINICS™ as the New Brand Name for its U.S. Brain PET Scanning Centers
Algernon Health to open brain-focused PET scanning clinic in Florida
Algernon to Open the First Brain Dedicated PET Scanning Clinic in the U.S. at the HCA Florida University Medical Office Building
Algernon Health completes final tranche of expanded private placement